Navigation Links
Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.

PORTOLA VALLEY, Calif., May 3 /PRNewswire/ -- Spectros announced today that it entered into a patent sale agreement with Koninklijke Philips Electronics N.V. ( PHG). Under this agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach first developed and patented by Spectros.

"We are pleased that Philips has recognized the value inherent in Spectros' intellectual property covering multispectral pulse oximetry," noted David Benaron, CEO. "Spectros has one of the largest optical biotechnology portfolios in the medical, sensing, and illumination markets."

Previously, Spectros has closed technology sale, license, or access agreements, including with LI-COR, Caliper Life Sciences, FirstScan, Merck Research, Rita Medical, and Boston Scientific Corporation.

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art white LEDs and broadband visible light spectroscopy (VLS) technology. The non-invasive T-Stat system is used clinically to provide an absolute, continuous, and real-time tissue oxygenation value, utilizing 260 wavelengths versus only 2-4 wavelengths for competing NIRS products. The Spectros T-Stat competes in the ICU oximetry marketplace with noninvasive devices from Somanetics, CAS Medical, and Masimo Corporation; and competes in the Plastic Surgery market with Vioptix.

Spectros is also developing Continuum and ProstaFluor molecular diagnostic tools for breast and prostate cancer, currently in phase I/II human clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only. T-Stat, FireFly, Continuum, VLS, and ProstaFluor are trademarks of Spectros).

SPECTROS CONTACT: For further information, visit, or contact Ms. Elizabeth van Thillo at or at (650) 529-2865.

SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
2. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
4. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
6. Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2010
7. Corgenix Medical Corp. Announces Launch of Products for Automated Systems
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
9. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
10. World Heart Corp. Completes $7.3 Million Private Placement
11. ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp.
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... announced that it has undertaken significant expansion of its current state of the ... is part of PharmaTech’s strategy to increase its manufacturing capacity as well as ...
Breaking Medicine News(10 mins):